Explore how ultra-sensitive proteomics is transforming biomarker discovery beyond traditional blood-based analyses.
The presentation will showcase how NULISA® technology and the ARGO™ HT System enable high-plex, ultra-sensitive protein detection across a wide range of novel and minimally invasive sample types, including dried blood and plasma spots.
The featured speaker, Dr. Niyati Jhaveri, Manager of the Technology Access Program at Alamar Biosciences, will discuss real-world translational and preclinical examples demonstrating how multiplexed proteomics can uncover disease-specific biology, assess therapeutic response and support scalable population-level research.
Join this webinar to learn how ultra-sensitive proteomic profiling from minimally invasive samples is reshaping disease biology and treatment insights across immunology, neuroscience and translational research.
Speaker
Niyati Jhaveri, PhD, Manager, Technology Access Program, Alamar Biosciences
Dr. Niyati Jhaveri leads the Technology Access Program at Alamar Biosciences and works closely with researchers across academia and biopharma on high plex proteomic profiling across a range of biofluids. Niyati graduated from the University of Southern California with a PhD in Genetic, Molecular and Cellular Biology with a focus on identifying novel therapies to treat recurrent glioblastoma. With over 10 years of experience in the biotech industry from spatial biology to ultrasensitive immunoassay technologies, Niyati has contributed to 14 publications and is passionate about next generation proteomics for accelerating precision medicine.
Message PresenterWho Should Attend?
This webinar is designed for scientists and researchers specializing in neurodegenerative disease research, biomarker discovery and proteomics as well as those working in the following areas or having the following job titles:
- Neuroscientists/Neurologists
- Biomarker/Proteomics Researchers
- Academic/Industry Scientists
- Clinical/Translational Researchers
- Pharmaceutical/Biotech professionals
What You Will Learn
Attendees will:
- Discover how ultra-sensitive proteomics are expanding beyond blood to generate insights from low-volume and non-traditional sample types, including dried blood spots
- Learn how NULISA technology delivers high-quality, multiplexed protein data from minimally invasive samples, enabling scalable studies without sacrificing sensitivity
- Explore real-world examples showing how advanced proteomic profiling reveals disease biology and treatment effects across immunology, neurosciences and translational research
Xtalks Partner
Alamar Biosciences
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels from biofluid samples. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method reducing background signal and increasing sensitivity and dynamic range compared with standard approaches. The NULISAseq™ CNS Disease Panel 120 provides ultra-sensitive and robust analysis of ~120 proteins to support protein biomarker discovery and validation studies and includes biomarkers such as pTau-217, GFAP and alpha-synuclein. In addition, the NULISAseq™ Inflammation Panel contains ~250 important markers enabling comprehensive analysis of immune and inflammatory diseases. The NULISA immunoassays run on the innovative ARGO™ HT System, allowing for a fully automated workflow with <30 minutes total hands-on time and comprehensive multiplex data analysis in <16 hours.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account